The global insulin-pen market is projected to grow to $41 billion by 2030 from about $34 billion in 2025, according to market research firm Mordor Intelligence.

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities. | Citing "capacity constraints ...

Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

An insulin pen manufactured by Novo Nordisk is displayed March 14, 2023, in Miami, Fla. (Joe Raedle/Getty Images / Getty Images) Novo Nordisk says it "remains committed to reducing the burden of ...

Novo Nordisk, a Danish drugmaker, will cut some insulin prices up to 75% next year, amid pressures from competitors and lawmakers alike. Hotspots ranked Start the day smarter ☀️ Funniest cap ...

MSF has identified price as a barrier to the use of insulin pens in LMICs. The nonprofit published a paper on insulin pen prices in March, in which it said the devices cost $1.99 in South Africa ...

Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

Novo Nordisk A/S has entered into exclusive negotiations for a controlling stake in Biocorp SA, suppliers of Mallya, a Bluetooth-enabled smart add-on device for insulin pen injectors. The takeover ...

In 1982, Novo marketed Human Monocomponent Insulin, and in 1987, ... Novo launched the NovoPen - the first insulin pen device in 1985. 2000–2017.